Vaccines

13 July 2016

Pfizer Receives FDA Approval for Prevnar 13® in Adults Age 18 Through 49

12 July 2016

New worldwide, exclusive license agreement provides broad access to Institut Pasteur’s virus vector technology – Zika vaccine development progressing with high priority

12 July 2016

VAXIMM initiates Phase 1 translational study in glioblastoma with oral T-cell immunotherapy, VXM01

7 July 2016

Valneva Announces Successful Generation of a Highly-purified Zika Vaccine Candidate Using its FDA-EMA Approved Japanese Encephalitis Platform

7 July 2016

Immunovaccine Announces Positive Interim Phase 1 Data for DepoVax(TM)-Based Respiratory Syncytial Virus Vaccine Candidate

1 July 2016

First-In-Human Study of Immbio’s Novel Pneumococcal Vaccine Pnubiovax Shows Vaccine to Be Safe and Immunogenic

30 June 2016

GeoVax Announces Filing of Investigational New Drug Application for HIV Human Clinical Trial

29 June 2016

Galena Biopharma Discontinues NeuVax™ (nelipepimut-S) Phase 3, PRESENT Interim Analysis based on Independent Data Monitoring Committee Recommendation

28 June 2016

Vaxart Initiates Clinical Development of First Oral RSV Vaccine

28 June 2016

DBV Technologies Announces Completion of Recruitment in Global Phase III Study of Viaskin Peanut for the Treatment of Peanut Allergic Children

23 June 2016

New Four-Strain Influenza Vaccine, VaxigripTetra™, Regulatory Dossier from Sanofi Pasteur Now Approved in Europe

23 June 2016

VBI Vaccines Begins Enrolling Patients in a Phase I Trial of its Preventative Cytomegalovirus Vaccine Candidate

23 June 2016

AstraZeneca provides update on Flumist Quadrivalent Vaccine in the US for the 2016-17 influenza season

22 June 2016

GeoVax Discusses Zika Vaccine Development at American Society for Virology’s 35th Annual Meeting

22 June 2016

Prima BioMed Announces First Safety, Pharmacokinetics and Immuno-Monitoring Data From Phase IIb Clinical Trial of IMP321

22 June 2016

AXON’s Pioneering Tau Vaccine against Alzheimer’s Started Phase II

21 June 2016

AiVita Biomedical Receives FDA Approval for Phase II Ovarian Cancer Treatment

21 June 2016

Circassia Announces Top-Line Results from Cat Allergy Phase III Study

20 June 2016

Takeda Initiates World’s First Norovirus Vaccine Field Trial

20 June 2016

Inovio Pharmaceuticals and GeneOne Life Science Receive Approval for First-in-Man Zika Vaccine Clinical Trial

20 June 2016

Vical’s Phase 1/2 Trial Data Presented at ASM 2016 Shows Bivalent Vaccine Imparts Reduction in Genital Herpes Lesions Durable to 9 Months

18 June 2016

SCIB1 Drug Product Supply

17 June 2016

FDA Accepts Emergent BioSolutions’ Supplemental Biologics License Application for Large-Scale Manufacturing of BioThrax in Building 55

11 June 2016

FDA Approves Vaxchora, PaxVax’s Single-Dose Oral Cholera Vaccine

8 June 2016

Immune Design Releases New PFS, OS and TME Data from Trials of Three Immuno-Oncology Product Candidates

7 June 2016

ImmunoCellular Therapeutics Treats First Patient in ICT-107 Phase 3 Registrational Trial in Newly Diagnosed Glioblastoma

7 June 2016

Galena Biopharma Presents GALE-301 Phase 1/2a Primary Analysis at the American Society of Clinical Oncology Annual Meeting 2016

7 June 2016

VAXIMM Presents Data from Phase I Trial in Pancreatic Cancer with Oral T-cell Immunotherapy VXM01 at ASCO 2016 Annual Meeting

5 June 2016

OBI Pharma Presents Data For Novel Investigational OBI-822/OBI-821 In Patients With Metastatic Breast Cancer At The 2016 American Society Of Clinical Oncology Annual Meeting

2 June 2016

Valneva´s Pseudomonas Aeruginosa Candidate (VLA43) Did Not Confirm Positive Vaccine Effect in Phase II/III trial

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

TROP-2-Targeted Immunotherapy Pipeline Review

5T4-Targeted Immunotherapy Candidates Pipeline Review

Targeted Protein Degradation by Novel PROTACs and Molecular Glues 2020: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

RNA-Targeted Novel Drug Modalities Based on RNA Editing, Epitranscriptomics, Direct RNA Targeting, Splicing Modulation, Translation Regulation, lncRNA & regRNA Targeting & More: a landscape analysis of technologies, targets, business and financing from an industry perspective

RNA-Targeted Small Molecules 2019: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financing

Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends

CD73 Inhibitor Pipeline Review

CCR8-Targeted Antibody Immunotherapy Pipeline Review